Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

To see complete record on, please visit this link

Id: NCT04656301

Organisation Name: New York State Psychiatric Institute

Overal Status: Completed

Start Date: February 26, 2021

Last Update: November 4, 2022

Lead Sponsor: New York State Psychiatric Institute

Brief Summary: In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin. Followup visits to monitor safety and clinical outcome will be conducted over a 3 month period.

  • Body Dysmorphic Disorders

Total execution time in seconds: 0.31074190139771